Pen injector carry case

Abstract

The present disclosure relates to a pen injector carry case (10) suitable for storing ac- cessories (2, 3) of a drug delivery device (1). The carry case (10) comprises an elongate body (11) with at least one compartment (13, 14) configured to receive accessories (2, 3) for the pen type a drug delivery device (1). The body (11) is a single-piece component part made of polypropylene (PP) or of high-density polyethylene (HDPE) and comprises a receiving channel (16) with a locking element configured to releasably fasten a pocket clip (4) the pen type a drug delivery device (1).

Description

[0001] Description

[0002] PEN INJECTOR CARRY CASE

[0003] The present disclosure is generally directed to improvements in sustainability of a pen injector carry case suitable for storing e.g. a spare cartridge and / or spare needles within their protective outer packaging or the like accessories.

[0004] Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having e.g. diabetes where self-treatment enables such patients to conduct effective management of their disease. In certain types of drug delivery devices, such as pen type devices, cartridges filled with a liquid drug are used. These cartridges are housed in a cartridge holder or cartridge housing. To dispense a dose of drug from such a cartridge, the drug delivery device has a dose setting and drive mechanism that uses a piston rod or lead screw moving in a distal direction and pressing the bung distally which expels a certain set dose of drug from the cartridge.

[0005] For such devices which provide for self-administration of a medicinal product from a multi-dose cartridge and permit a user to individually set a variable delivery dose, there is a general distinction between devices which are intended to be reused when the cartridge is empty by replacing the empty cartridge by a new cartridge, e.g. a device as disclosed in WO 2014 / 033195 A1 and devices which are intended to be disposed of when the cartridge is empty, e.g. a device as disclosed in EP 1 603 611 B1.

[0006] Users often carry such devices in a carry case which does not only protect the device itself but which also provides space for storing accessory parts, like spare needles within their protective outer packaging and / or, for reusable devices, a spare cartridge. Existing carry cases are often primarily constructed from woven nylon fabric, which has a poor environmental sustainability profile. Such a textile carry case is known for example from FR 2 892 095 A1. Further, such carry cases typically consist of a mix of different

[0007] 16. Dezember 2025 S 100 P 556 WO materials, including metal parts for a zipper, different plastic materials, fabric or imitation leather, which are not suitable to be recycled in a common waste stream. An example of a carry case consisting of different materials is known from US 2005 / 084631 A1. An additional drawback of some known carry cases is that they are quite bulky making it difficult to carry them in a trouser or jacket pocket, like the carry cases disclosed for example in US 2013 / 131607 A1 or US 2008 / 289984 A1.

[0008] It is an object of the present disclosure to provide an improved carry case for a pen injector that stores and protects at least the device.

[0009] This object is solves with a carry case according to claim 1.

[0010] A pen injector carry case according to the present disclosure is suitable for storing accessories of a drug delivery device, especially of a drug delivery device with a pocket clip. The carry case may comprise an elongate body with at least one compartment configured to receive one or more accessories for the pen type a drug delivery device. According to the present disclosure, the body is a single-piece component part made of polypropylene (PP) or of high-density polyethylene (HDPE) other materials with a good sustainability profile and may comprise a receiving channel with a locking element configured to releasably fasten a portion of the drug delivery device, especially a pocket clip of the pen type a drug delivery device.

[0011] The carry case according to the present disclosure is a sustainable carry case that stores pen injector accessories. The proposed configuration and structure enables a solution constructed from more sustainable materials and processes, for example injection moulded PP or HDPE which are suitable for medical device applications and high-volume mass production techniques. The proposed carry case provides a number of sustainability benefits, especially compared to known carry cases made of nylon and other materials. For example, PP or HDPE has a lower embodied energy than nylon fabric, meaning less energy is used during manufacture, reducing carbon generation. Further, PP and HDPE are already widely recycled materials with established recycling streams, meaning it can potentially be both manufactured using recycled material and can be fed into existing recycling streams post use. In addition, the carry case is capable of being a mono-

[0012] 16. Dezember 2025 S 100 P 556 WO material product. This simplifies the process for recycling, removing the need for disassembly to separate different material types. This reduces the energy used for recycling, and increases the quality of material that may be efficiently recycled. Further, the carry case is more compact than known carry cases, which enables the size of secondary packaging to be minimised, which can increase the packaging density and efficiency of the refrigerated supply chain (reducing energy use and carbon).

[0013] In addition, the use of PP or HDPE material for construction and a minimisation of components and assembly steps provide significant cost benefits in comparison with current carry case solutions. It should be noted that other materials, e.g. PE, with a similar good sustainability profile may be used for the construction of the body of the carry case. The body may be an injection moulded component made using, e.g. PP or HDPE.

[0014] According to an example how the carry case of the present disclosure can contain different accessories, the body may comprise a first compartment configured to store a spare drug cartridge and a second compartment configured to store one or more spare needles. Removal of such accessories from the body may be facilitated if each compartment comprises an opening closable by a hinged door. Such a door may be a single-piece component part with the body. For example, the body may be substantially tubular with doors provided at opposite ends thereof.

[0015] The carry case is intended to be attached to a drug delivery device by means of the pocket clip which may be inserted into the receiving channel. For this purpose, the receiving channel may extend substantially parallel to the at least one compartment. For example, the receiving channel may be provided adjacent to and substantially parallel to the first compartment for the cartridge.

[0016] If the accessories are a spare cartridge and one or more, e.g. three, spare needles within their protective outer packaging, the length of the second compartment for the needles may exceed the length of the first compartment. In addition or as an alternative, the width of the second compartment may exceed the width of the first compartment. The carry case may have a body with a non-circular cross-section. The non-circular cross-section may be elliptical or oval.

[0017] 16. Dezember 2025 S 100 P 556 WO In an example of the present disclosure, the first compartment may be separated from the second compartment by an internal partition wall of the body, thereby defining two compartments within the body.

[0018] According to an independent aspect of the present disclosure, a pen injector carry case is provided which is suitable for storing accessories of a drug delivery device and which is suitable for attaching a drug delivery device which comprises a pocket clip. The carry case of this example comprises an elongate body with at least two compartments configured to receive accessories for the pen type a drug delivery device. The body comprises a receiving channel with a locking element configured to releasably fasten a pocket clip of the pen type a drug delivery device. The receiving channel is provided adjacent to and substantially parallel to the first compartment wherein the width of the second compartment exceeds the width of the first compartment such that the width of the second compartment may substantially correspond to the combined widths of the receiving channel and the first compartment. This allows a slim design of the carry case without bulky protruding portions. Preferably, the body is a single-piece component part made of polypropylene (PP) or of high-density polyethylene (HDPE), i.e. a unitary component which may be integrally formed together with optional doors for closing the compartments e.g. by injection moulding.

[0019] According to an aspect of the present disclosure, the locking element may comprise a latching element or snap-fit element configured to secure the pocket clip of the drug delivery device in a releasable manner in the receiving channel. In addition or as an alternative, the size and shape of the receiving channel may be adapted to the size and shape of the pocket clip such that the pocket clip may be retained in the receiving channel by friction.

[0020] The pocket clip may be provided on any suitable portion of the drug delivery device. For example, the pocket clip may be provided on a removable cap of the drug delivery device or on a housing portion.

[0021] 16. Dezember 2025 S 100 P 556 WO According to a further aspect of the present disclosure, the carry case comprises the pocket clip of a pen type a drug delivery device fastened in the receiving channel such that the drug delivery device is releasably attached to the carry case. The first compartment may comprise a cartridge filled with a liquid drug and the second compartment may comprise at least one injection needle. In other words, the present disclosure includes a set or an assembly comprising the carry case and a pen type drug delivery device, e.g. a drug delivery device as disclosed in WO 2014 / 033195 A1 or in EP 1 603 611 B1.

[0022] The terms “drug” or “medicament” are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier. An active pharmaceutical ingredient (“API”), in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.

[0023] As described below, a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Examples of API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

[0024] The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed

[0025] 16. Dezember 2025 S 100 P 556 WO to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20°C), or refrigerated temperatures (e.g., from about - 4°C to about 4°C). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and / or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.

[0026] The drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and / or prophylaxis of many different types of medical disorders. Examples of disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.

[0027] Examples of APIs for the treatment and / or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms “analogue” and “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and / or exchanging at least one amino acid residue occurring in the naturally occurring peptide and / or by adding at least one amino acid

[0028] 16. Dezember 2025 S 100 P 556 WO residue. The added and / or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogues are also referred to as "insulin receptor ligands". In particular, the term ..derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g. a fatty acid) is bound to one or more of the amino acids. Optionally, one or more amino acids occurring in the naturally occurring peptide may have been deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codea- ble, have been added to the naturally occurring peptide.

[0029] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Vai or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0030] Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N- tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-pal- mitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)- des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl- des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glu- tamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(w-carboxyheptadecanoyl) human insulin.

[0031] Examples of GLP-1 , GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®), Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Vic- toza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rEx- endin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C (Efpegle- natide), HM-15211 , CM-3, GLP-1 Eligen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1 , ZYD-1 , GSK-

[0032] 16. Dezember 2025 S 100 P 556 WO 2374697, DA-3091 , MAR-701 , MAR709, ZP-2929, ZP-3022, ZP-DI-70, TT-401 (Pega- pamodtide), BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651 , ARI-2255, Tir- zepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon- Xten.

[0033] An example of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia or RG012 for the treatment of Alport syndrom.

[0034] Examples of DPP4 inhibitors are Linagliptin, Vildagliptin, Sitagliptin, Denagliptin, Sax- agliptin, Berberine.

[0035] Examples of hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Fol litropi n, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.

[0036] Examples of polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above- mentioned polysaccharides, and / or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.

[0037] The term “antibody”, as used herein, refers to an immunoglobulin molecule or an anti- gen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments, which retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. The term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or a dual variable region anti- body-like binding protein having cross-over binding region orientation (CODV).

[0038] 16. Dezember 2025 S 100 P 556 WO The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and / or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigenbinding antibody fragments are known in the art.

[0039] The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.

[0040] Examples of antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).

[0041] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are for example acid addition salts and basic salts.

[0042] Those of skill in the art will understand that modifications (additions and / or removals) of various components of the APIs, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and

[0043] 16. Dezember 2025 S 100 P 556 WO spirit of the present invention, which encompass such modifications and any and all equivalents thereof.

[0044] An example drug delivery device may involve a needle-based injection system as described in Table 1 of section 5.2 of ISO 11608-1 :2014(E). As described in ISO 11608- 1 :2014(E), needle-based injection systems may be broadly distinguished into multidose container systems and single-dose (with partial or full evacuation) container systems. The container may be a replaceable container or an integrated non-replaceable container.

[0045] As further described in ISO 11608-1 :2014(E), a multi-dose container system may involve a needle-based injection device with a replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user). Another multi-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user). As further described in ISO 11608-1 :2014(E), a single-dose container system may involve a needle-based injection device with a replaceable container. In one example for such a system, each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation). In a further example, each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation). As also described in ISO 11608-1 :2014(E), a single-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In one example for such a system, each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation). In a further example, each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).

[0046] In the following, non-limiting, examples of a carry case for a drug delivery device are described in more detail by making reference to the drawings, in which:

[0047] Figure 1 shows a front view of a carry case according to the present disclosure with an attached pen type drug delivery device;

[0048] 16. Dezember 2025 S 100 P 556 WO Figure 2 shows a sectional view of the carry case of Figure 1 with an attached pen type drug delivery device;

[0049] Figure 3 shows a perspective view of the carry case of Figure 1 with an attached pen type drug delivery device; and

[0050] Figures 4A-D show details of the carry case of Figure 1.

[0051] The Figures show an example of a carry case 10 for a pen type drug delivery device 1 and accessories for the drug delivery device, here a spare cartridge 2 and spare needles 3 within their protective outer packaging.

[0052] The carry case 10 is substantially formed by a body 11 made as a single piece injection moulded component part made from PP or another suitable material, like HDPE. In other words, the carry case is constructed from a single component, namely the carry case body 11. The body 11 is a tubular element having an internal partition wall 12 such that two compartments 13, 14 are defined. Each compartment 13, 14 may have a hinged door 15 made as a single piece component part with the body 11 . Further, the body comprises a receiving channel 16 arranged adjacent to and parallel to the first compartment 13. The receiving channel 16 is open on one side of the body (upper end in Figure 1) and may comprise a locking element (not shown) configured to releasably fasten a pocket clip 4 of the pen type drug delivery device 1.

[0053] The pen type drug delivery device 1 may comprise a removable cap 5 that includes the pocket clip 4 which is able to slide and clip into the receiving channel 16 in the body 11. This enables the drug delivery device 1 and the carry case 10 to be used and stored separately, or joined together as required by a user.

[0054] In more detail, the body 11 consists of two separate chambers or compartments 13, 14, namely a first compartment 13 which is an upper chamber as seen in Figure 2 in which a spare drug cartridge 2 may be stored, and a second compartment 14 which is a lower chamber as seen in Figure 2 in which up to three spare needles 3 within their protective outer packaging may be stored. As can be seen in Figure 2, the length and the width of

[0055] 16. Dezember 2025 S 100 P 556 WO the first compartment 13 is smaller than the length and the width of the second compartment 14. Thus, the outer shape of the body 11 may remain substantially the same although the receiving channel 16 is provided side by side next to the first compartment 13.

[0056] These chambers are formed as part of the single carry case body 11 , and each one includes the hinged door that can be closed and opened by the user in order to store the cartridge 2 and needle 3 accessories as indicated in Figures 4C and 4D. The hinged doors may be formed as part of the single carry case body 11 using a live hinge in the PP material. Each door 15 may include a clip feature that ensures the contents are secure and may only be accessed via a deliberate action by the user.

[0057] The separate chamber (first compartment 13) for the cartridge 2 ensures that any drug leakage (e.g. due to a broken cartridge) is contained and cannot contaminate the device, or needle storage area.

[0058] As an alternative to the depicted example, the hinged doors could be separate components, or only a single chamber could be provided.

[0059] The proposed carry case design provides a number of sustainability benefits including a lower embodied energy, a widely recycled material with established recycling streams, a mono-material product with simplified recycling process and a more compact design.

[0060] 16. Dezember 2025 S 100 P 556 WO Reference Numerals

[0061] 1 drug delivery device

[0062] 2 cartridge

[0063] 3 needle

[0064] 4 pocket clip

[0065] 5 cap

[0066] 10 carry case

[0067] 11 body

[0068] 12 partition wall

[0069] 13 first compartment (chamber)

[0070] 14 second compartment (chamber)

[0071] 15 hinged door

[0072] 16 receiving channel

[0073] 16. Dezember 2025 S 100 P 556 WO

Claims

Claims1. A pen injector carry case suitable for storing accessories (2, 3) of a drug delivery device (1) which drug delivery device (1) comprises a pocket clip (4), the carry case (10) comprising an elongate body (11) with at least one compartment (13, 14) configured to receive accessories (2, 3) for the pen type a drug delivery device (1), characterized in that the body (11) is a single-piece component part made of polypropylene (PP) or of high-density polyethylene (HDPE) and comprises a receiving channel (16) with a locking element configured to releasably fasten a pocket clip (4) of the pen type a drug delivery device (1).

2. The carry case according to claim 1 , wherein the body (11) is an injection moulded component made using polypropylene (PP) or high-density polyethylene (HDPE).

3. The carry case according to claim 1 or 2, wherein the body (11) comprises a first compartment (13) configured to store a spare drug cartridge (2) and a second compartment (14) configured to store one or more spare needles (3).

4. The carry case according to any one of the preceding claims, wherein each compartment comprises an opening closable by a hinged door (15) which is a single-piece component part with the body (11).

5. The carry case according to claim 4, wherein the body (11) is substantially tubular with doors (15) provided at opposite ends thereof.

6. The carry case according to any one of the preceding claims, wherein the receiving channel (16) extends substantially parallel to the at least one compartment (13, 14).

7. The carry case according to any one of claims 3 to 6, wherein the receiving channel (16) is provided adjacent to and substantially parallel to the first compartment (13).

16. Dezember 2025 S 100 P 556 WO8. The carry case according to any one of claims 3 to 7, wherein the length of the second compartment (14) exceeds the length of the first compartment (13) and / or wherein the width of the second compartment (14) exceeds the width of the first compartment (13).

9. The carry case according to any one of claims 3 to 8, wherein the first compartment (13) is separated from the second compartment (14) by an internal partition wall (12) of the body (11).

10. The carry case according to any one of the preceding claims, wherein the body(11) has a non-circular cross-section.11 . The carry case according to any one of the preceding claims, wherein the locking element comprises a latching element or snap-fit element.

12. The carry case according to any one of the preceding claims, wherein the pocket clip (4) of a pen type a drug delivery device (1) is fastened in the receiving channel (16) and wherein the first compartment (13) comprises a cartridge (2) filled with a liquid drug and the second compartment (14) comprises at least one injection needle (3).

16. Dezember 2025 S 100 P 556 WO

Images